RhumbLine Advisers’s Century Therapeutics IPSC Stock Holding History

RhumbLine Advisers’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$215K	Sell	125,548 -2,856	-2%	-$5.85K	﹤0.01%	3241
2026 Q2	$315K	Buy	+128,404	New	+$293K	﹤0.01%	3046
2025 Q2	–	Sell	-43,273	Closed	-$20.6K	–	4198
2025 Q1	$20.6K	Buy	43,273 +182	+0.4%	+$137	﹤0.01%	3733
2024 Q4	$43.5K	Sell	43,091 -6,771	-14%	-$9.22K	﹤0.01%	3677
2024 Q3	$85.3K	Sell	49,862 -2,604	-5%	-$5.1K	﹤0.01%	3548
2024 Q2	$134K	Buy	52,466 +18,828	+56%	+$59.5K	﹤0.01%	3416
2024 Q1	$141K	Buy	33,638 +692	+2%	+$2.93K	﹤0.01%	3331
2023 Q4	$109K	Sell	32,946 -1,256	-4%	-$2.29K	﹤0.01%	3422
2023 Q3	$68.4K	Buy	34,202 +750	+2%	+$2K	﹤0.01%	3576
2023 Q2	$106K	Buy	33,452 +2,350	+8%	+$7.58K	﹤0.01%	3508
2023 Q1	$108K	Buy	31,102 +363	+1%	+$1.59K	﹤0.01%	2846
2022 Q4	$158K	Buy	30,739 +222	+0.7%	+$2.1K	﹤0.01%	2840
2022 Q3	$302K	Buy	30,517 +1,939	+7%	+$20.4K	﹤0.01%	2725
2022 Q2	$240K	Buy	28,578 +13,617	+91%	+$134K	﹤0.01%	2857
2022 Q1	$188K	Buy	+14,961	New	+$198K	﹤0.01%	2772
2021 Q4	–	Sell	-8,697	Closed	-$219K	–	3009
2021 Q3	$219K	Buy	+8,697	New	+$235K	﹤0.01%	2877

Other funds holding IPSC

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

RhumbLine Advisers's IPSC Position: Q3 2026 in Review

RhumbLine Advisers reduced its Century Therapeutics (IPSC) stake by 2.2% in Q3 2026, selling an estimated $5.85K and leaving 125,548 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #3241.

RhumbLine Advisers first reported a position in IPSC in Q3 2021 and has held it in 16 quarters since. The position peaked at $315K in Q2 2026. 33 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.

RhumbLine Advisers held 125,548 shares of Century Therapeutics worth $215K as of Q3 2026.
RhumbLine Advisers sold 2,856 Century Therapeutics shares in Q3 2026, an estimated $5.85K.
Century Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3241 holding.
RhumbLine Advisers first reported a position in Century Therapeutics in Q3 2021 and has held it in 16 quarters since.
RhumbLine Advisers's Century Therapeutics position peaked at $315K in Q2 2026.
33 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.